BSX Boston Scientific Loading... : Bullish and Bearish Analyst Opinions
From ABT earnings callsLoading chart...
Top Calls
Feed
13:00
Jul 16
Jul 16
Electrophysiology share inflection: Volt 2.0 goes from limited to full U.S. market release in Q3, and European EP sales grew over 20% on Volt/TactiFlex Duo rollout. — PFA competition is shifting; Abbott's launch momentum and mapping integration threaten the leading EP players' share in the highest-growth ablation category.
MED
14:00
Jan 22
Jan 22
The electrophysiology (EP) market is shifting towards a 'toolbox' approach where physicians will use both balloon/basket and dual-energy catheters depending on patient profiles, with Abbott positioning its Volt and TactiFlex Duo as complementary rather than competing. — This implies that the competitive battleground will be about portfolio breadth and physician preference, not just who has the fastest single catheter, potentially mitigating the impact of Boston Scientific's (BSX) earlier PFA launches.
MED
About BSX Analyst Coverage
Buzzberg tracks BSX (Boston Scientific) across 1 sources. 0 bullish vs 0 bearish calls from 1 analysts. Sentiment: evenly split. 2 total trade ideas tracked. Latest voices: Robert Ford.